[
  {
    "Column1": 0,
    "target_name": "EGFR",
    "0": "example target info [ref123456]",
    "1": "kinase inhibitor",
    "2": "epidermal growth factor receptor",
    "3": "tyrosine kinase inhibitor",
    "4": "gefitinib",
    "5": "erlotinib",
    "6": "afatinib",
    "7": "EGFR mutation positive",
    "8": "non-small cell lung cancer",
    "9": "approved by FDA",
    "10": "clinical trials phase III",
    "11": "unii-12345abcde",
    "12": "targeted therapy",
    "13": "monoclonal antibody",
    "14": "small molecule",
    "15": "chembl1234567",
    "16": "schembl7654321",
    "17": "inhibitor class I",
    "18": "inhibitor class II"
  },
  {
    "Column1": 1,
    "target_name": "HER2",
    "0": "example target info [ref654321]",
    "1": "monoclonal antibody",
    "2": "human epidermal growth factor receptor 2",
    "3": "breast cancer",
    "4": "trastuzumab",
    "5": "pertuzumab",
    "6": "lapatinib",
    "7": "HER2 positive",
    "8": "approved by EMA",
    "9": "clinical trials phase II",
    "10": "unii-67890fghij",
    "11": "targeted therapy",
    "12": "antibody-drug conjugate",
    "13": "small molecule inhibitor",
    "14": "chembl0987654",
    "15": "schembl8765432",
    "16": "inhibitor class III",
    "17": "inhibitor class IV",
    "18": "combination therapy"
  }
]